Provided is a test strip for detecting human chorionic gonadotropin (HCG) in saliva and a preparation method thereof, and belongs to the technical field of test strip detection. each 100 mL of the sample pad treatment solution includes the following components: 1.0 g to 1.5 g of Tris, 0.3 g to 0.8 g of casein, 50 L to 100 L of Tween-20, 0.5 g to 1.5 g of NaCl, 0.15 g to 0.2 g of dodecyltrimethylammonium bromide (DTAB), 0.8 g to 1.2 g of 4-nonylphenyl-polyethylene glycol, 3.5 g to 4.0 g of borax, 0.5 g to 1 g of polyvinylpyrrolidone (PVP), 3 g to 5 g of dithiothreitol (DTT), and 0.8 g to 2 g of L-cysteine. The test strip shows high sensitivity and desirable stability, can be stored at a room temperature for a long time and is not affected by the time and place of sample collection.

A pregnancy monitoring device and method improve detection in the first trimester of the occurrence of ectopic pregnancy and the occurrence of multiple foetuses. The device includes a sample absorbing member and an analyser to analyse a plurality of sequential a biological liquid samples and computing means to determine an ovulation date and deviations in the measured quantity of hCG from predetermined values which are indicators of ectopic pregnancy or multiple pregnancy. The device and method enables early detection of ectopic pregnancy or multiple pregnancy.

The invention relates to antibody characteristics used to design a whole blood Point of Care Thyroid Stimulating Hormone (TSH) immunoassay using an ELISA sandwich assay lacking one or more wash steps between the antigen capture, detection antibody addition and substrate introduction steps. This invention exhibits low cross reactivity with biologically similar interfering cross reacting species, such as Follicle Stimulating Hormone (FSH), Luteinizing Hormone (LH) and Chorionic Gonadotropin (CG).

The invention relates to low wash Thyroid Stimulating Hormone (TSH) immunoassays using an ELISA sandwich assay having limited or no wash step between the antigen capture, detection antibody addition and substrate introduction steps. This invention exhibits low cross reactivity with biologically similar interfering cross reacting species, such as Follicle Stimulating Hormone (FSH), Luteinizing Hormone (LH) and Chorionic Gonadotropin (CG).

Provided are an immunochromatography kit that is highly sensitive and capable of multicoloration, and organic colored microparticles that are ideal as an element of the immunochromatography kit. Organic colored microparticles having an average grain size between 10 and 1,000 nm and a color intensity between 1.0 and 5.0 are prepared using cellulose as the starting material. When the organic colored microparticles are used as a label in an immunochromatography kit, the immunochromatography kit is of a high sensitivity than conventional technology. The immunochromatography kit is also capable of multicoloration and is useful for rapid diagnosis.

A device and method for detecting a plurality of analytes of interest in a sample are disclosed. The device has a first portion for detection of a first analyte of interest, and a second test portion for detection of a second analyte of interest. The first test portion has a test membrane with a chemical reaction side having a reaction mixture blotted thereon. The second test portion has a conjugate pad having detector particles bound thereon and an immunoreaction membrane having a test zone comprising a test antibody bound thereon, and a control zone comprising a control antibody bound thereon. The first test portion is in fluid-flow contact with the second test portion, arranged for transporting the sample away from the first test portion towards the second test portion.

The invention relates to biomarkers and methods of diagnosing or monitoring schizophrenia, or a predisposition thereto.

The present invention provides a method of predicting pregnancy outcome in a subject by determining the amount of an early pregnancy associated molecular isoform of hCG in a sample. The present invention further provides a method for determining the amount of early pregnancy associated molecular isoforms of human chorionic gonadotropin (hCG) in a sample. The present invention also provides a diagnostic kit for determining the amount of early pregnancy associated hCG in a sample. The present invention additionally provides an antibody which specifically binds to an early pregnancy associated molecular isoform of human chorionic gonadotropin. Finally, the present invention provides methods for detecting trophoblast or non-trophoblast malignancy in a sample.

Disclosed is a covalently-linked multilayered three-dimensional matrix comprising capture molecules, linkers and spacers (referred to as a Molecular Net) for specific and sensitive analyte capture from a sample. Also disclosed herein is a Molecular Net comprising covalently-linked multilayered three-dimensional matrix comprising more than one type of capture molecule and more than one type of linker and may comprise one or more spacer for specific and sensitive capture of more than one type of analyte from a sample. A Molecular Net may comprise a pseudorandom nature. Use of various capture molecules, linkers and spacers in a Molecular Net may confer unique binding properties to a Molecular Net. Porosity, binding affinity, size exclusion abilities, filtration abilities, concentration abilities and signal amplification abilities of a Molecular Net may be varied and depend on the nature of components used in its fabrication. Uses of a Molecular Net may include analyte capture, analyte enrichment, analyte purification, analyte detection, analyte measurement and analyte delivery. Molecular Nets may be used in liquid phase or on solid phases such as nanomaterials, modified metal surfaces, nanospheres, microspheres, microtiter plates, slides, pipettes, cassettes, cartridges, discs, probes, lateral flow devices, microfluidics devices, microfluidics devices, optical fibers and others.

The present disclosure relates to diagnostic test devices that provide improved communication to a user of one or both of proper functioning of the test device and an analog test result that is provided by the test device. The diagnostic test devices particularly can include one or more sensors effective to indicate application of a sufficient volume of a test fluid and/or can include one or more light sources positioned to illuminate an analog test result for improved visibility and understanding of the analog test result.